[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
3. Jung SH, Kim HC, Yu CS, Chang HM, Ryu MH, Lee JL, Kim JS, Kim JC: [Clinicopathologic characteristics of colorectal neuroendocrine tumor]. Korean J Gastroenterol; 2006 Aug;48(2):97-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics of colorectal neuroendocrine tumor].
  • BACKGROUND/AIMS: Colorectal neuroendocrine carcinoma is a rare neoplasm exhibiting fulminant progression and having poor prognosis.
  • Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse colon and cecum, respectively.
  • All patients were advanced at the time of diagnosis, with AJCC TNM staging: stage IIIB (n=2), stage IIIC (n=3), and stage IV (n=8).
  • Five patients who received chemotherapy showed median survival of 32 months (stage III) and 17.5 months (stage IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.
  • Nevertheless, improved survival may be achieved by aggressive multimodality therapy.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929153.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
  •  go-up   go-down


Advertisement
4. Nakamura K, Nakamura T, Kurachi K, Fukazawa A, Hayashi T, Nakajima A, Suzuki S, Konno H: [A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. Gan To Kagaku Ryoho; 2008 Jun;35(6):1017-20
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
  • The patient was diagnosed with sigmoid colon cancer using colonoscopy.
  • Abdominal CT revealed metastases to para-aortic lymph node, so our diagnosis was unresectable sigmoid colon cancer.
  • She underwent a transverse colostomy to avoid stenosis.
  • Two weeks after surgery, she underwent a 1-week chemotherapy regimen (CPT-11 80 mg/m(2)/week+5-FU 2,000 mg/m(2)/week+l-LV 250 mg/m(2)/week) modified AIO regimen combined irinotecan for 3 weeks, followed by a 1-week rest interval as one course.
  • Throughout the period of treatment, there was no adverse event, and this regimen has been maintained for 5 courses.
  • After 5 courses of chemotherapy, primary tumor and metastases to para-aortic lymph nodes were remarkably reduced on colonoscopy and abdominal CT.
  • This combination therapy may well be useful for advanced colon cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta / pathology. Camptothecin / analogs & derivatives. Fluorouracil / therapeutic use. Leucovorin / therapeutic use. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiography. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633237.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Fujisaki S, Takashina M, Tomita R, Takayama T: [Improvements in quality of life and survival of patients with T4 gastric cancer which invaded organs after multivisceral resections through the extension of palliative gastrectomy and post-operative chemotherapy]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1881-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvements in quality of life and survival of patients with T4 gastric cancer which invaded organs after multivisceral resections through the extension of palliative gastrectomy and post-operative chemotherapy].
  • This study was designed to evaluate improvements in quality of life and survival of patients with T4 gastric cancer which invaded organs exhibiting bleeding or obstruction, after multivisceral resections of these organs through the extension of palliative gastrectomy and postoperative chemotherapy.
  • The sites of the organs invaded were the pancreas in five cases, and transverse colon and gallbladder in one case.
  • Chemotherapy (TS-1 plus CDDP) was started with 3 patients during their stay in the hospital.
  • In addition, post-operative chemotherapy (TS-1) at the outpatient clinic was performed on 5 of the 6 patients.
  • The median survival time was more than 419.5 days.
  • In conclusion, we consider that multivisceral resections through the extension of palliative gastrectomy and postoperative chemotherapy for patients with T4 gastric cancer could improve quality of life and prognosis.
  • [MeSH-major] Gastrectomy. Quality of Life. Stomach Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colonic Neoplasms / pathology. Female. Gallbladder Neoplasms / pathology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Palliative Care. Pancreatic Neoplasms / pathology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212135.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Iitaka D, Ikoma H, Kawaguchi T, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Ochiai T, Kokuba Y, Sonoyama T, Konishi H, Yoshikawa T, Otsuji E: [A case report--locally advanced pancreatic adenocarcinoma was resected after chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2358-60
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report--locally advanced pancreatic adenocarcinoma was resected after chemotherapy].
  • Upper gastrointestinal endoscopy revealed circumferential stenosis in the fourth portion of the duodenum, while CT revealed a tumor with a diameter of 60 mm continuing as a single mass from the pancreatic body and tail to the fourth portion of the duodenum, and this was accompanied by findings that raised suspicions of circumferential invasion of the superior mesentric artery (SMA).
  • The tumor response was PR and the images indicated the SMA invasion was disappeared.
  • We judged that the tumor could be gone by a resection while preserving the SMA.
  • In the surgical findings, the tumor continued as a single mass from the pancreatic body and tail to the third portion of the duodenum, and the surrounding area exhibited marked fibrosis.
  • We performed a pancreatic tail resection along with combined resection of third and fourth portions of the duodenum, transverse colon and splenic flexure, and left adrenal gland.
  • In this case, the treatment was initially started by considering the case as one of duodenal cancer, but the final results of a pathological diagnosis revealed that it was pancreatic cancer.
  • However, either way, even though the case was unresectable before the chemotherapy performed for duodenal cancer was significantly effective for the pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Duodenal Neoplasms / pathology. Duodenal Neoplasms / therapy. Humans. Male. Mesenteric Artery, Superior / pathology. Neoplasm Invasiveness. Oxonic Acid / administration & dosage. Taxoids / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224572.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Hasegawa K, Matsumoto R, Yamada H, Kuroda T, Mamiya Y, Kon A: [A case of sigmoid colon carcinoma accompanied with hydronephrosis caused by peritoneal dissemination and para-aortic lymph node metastases markedly responded to chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2213-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sigmoid colon carcinoma accompanied with hydronephrosis caused by peritoneal dissemination and para-aortic lymph node metastases markedly responded to chemotherapy].
  • The patient was a 64-year-old male diagnosed as advanced sigmoid colon cancer accompanied with hydronephrosis caused by peritoneal dissemination and para-aortic lymph node metastases.
  • We performed transverse colostomy in the end of June 2008.
  • He received chemotherapy with LV+5-FU in the middle of August, continuously with bevacizumab (BV)+mFOLFOX6 in the end of October.
  • In December, an elevated CEA marker was decreased after these treatments.
  • Histologically, most mucinous carcinoma cells disappeared or denatured, with viable tumor cells slightly remained.
  • [MeSH-major] Hydronephrosis / etiology. Neoplasm Seeding. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta, Abdominal. Bevacizumab. Colostomy. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Peritoneal Cavity

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037374.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


8. Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, Iacopetta B: p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology; 2000;58(1):52-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.
  • Two common genetic alterations in colon carcinoma, p53 mutation and microsatellite instability (MSI), were investigated to determine their prognostic importance for cancer-specific survival and response to adjuvant chemotherapy in patients with Dukes' C colon cancer.
  • The p53 tumour suppressor gene encodes for a nuclear phosphoprotein involved in cellular response to DNA damage, while MSI is a characteristic feature of tumours with defective DNA mismatch repair.
  • The cellular response mechanisms to DNA-damaging agents in tumours with mutant p53 or MSI may as a consequence differ, and this might translate into different outcomes following adjuvant chemotherapy.
  • A consecutive series of 388 Dukes' C colon carcinomas with 5-year median follow-up was analysed for p53 mutation and for MSI (in proximal/transverse carcinomas only) using polymerase chain reaction single-strand conformation polymorphism.
  • The incidence of p53 mutation was 28% in all carcinomas while that of MSI in proximal/transverse carcinomas was 19%.
  • One hundred and thirty-three patients (34%) received adjuvant chemotherapy (5-fluorouracil/levamisole) with curative intent.
  • The presence of MSI in the proximal/transverse colon carcinoma group was associated with significantly better 5-year survival: 58 versus 32% (p = 0.015, log rank test).
  • This was largely due to better survival observed in the MSI subgroup that received adjuvant chemotherapy (p = 0.017, log rank test).
  • Further work in prospective, randomised clinical trials investigating the effects of adjuvant therapy should consider incorporating MSI status in order to determine whether this is an independent predictive factor for survival and/or response to adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / genetics. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Genes, p53 / genetics. Microsatellite Repeats. Mutation
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Levamisole / administration & dosage. Male. Neoplasm Staging. Polymerase Chain Reaction / methods. Polymorphism, Single-Stranded Conformational. Predictive Value of Tests. Prognosis. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10644941.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Fukuda Y, Fujio N, Ihara T, Takatori H, Tsukazaki T, Koyama I, Tsukazaki Y, Osugi H: [A case of advanced gastric cancer with direct invasion of the transverse colon responding to paclitaxel/5'-DFUR combined therapy]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1945-8
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with direct invasion of the transverse colon responding to paclitaxel/5'-DFUR combined therapy].
  • A 50-year-old man was diagnosed with non-resectable scirrhous gastric cancer of antrum accompanied with colon ileus due to direct invasion of the transverse colon.
  • As the ileus improved after cecostomy, chemotherapy with TS-1/cisplatin(CDDP) was performed.
  • Because of no response, 4 cycles of paclitaxel (PTX)/doxifluridine (5'-DFUR) therapy was performed as second-line chemotherapy.
  • Since the stenosis of transverse colon dilated completely and the tumor disappeared, we performed total gastrectomy and right hemicolectomy, and could resect completely.
  • Though 2 cycles of PTX/5'-DFUR therapy was performed postoperatively and the patient's postoperative condition was good, he was suffering from carcinomatous peritonitis complicated by ileus and obstructive jaundice 4 months after operation.
  • PTX/5'-DFUR therapy, which has only slight complications, may be useful for patients with recurrent gastric cancer who had been treated with 5-FU administration as first-line chemotherapy.
  • But the future problem was how to control dissemination after surgery in a resectable case after chemotherapy.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colon, Transverse / pathology. Colonic Neoplasms / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Floxuridine / administration & dosage. Humans. Ileus / etiology. Male. Middle Aged. Neoplasm Invasiveness. Paclitaxel / administration & dosage. Peritoneal Neoplasms / secondary. Quality of Life

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282732.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


10. Yoshida N, Kochi M, Niide O, Watanabe Y, Mamiya T, Mochizuki S, Ohkubo T, Takayama T: [A case of advanced sigmoid colon cancer with peritoneal dissemination responding to FOLFOX4 therapy]. Gan To Kagaku Ryoho; 2008 Dec;35(13):2429-32
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced sigmoid colon cancer with peritoneal dissemination responding to FOLFOX4 therapy].
  • A 62-year-old woman complained of thin feces, lower blood and abdominal pain, and she was diagnosed as having bowel obstruction due to sigmoid colon cancer.
  • We established a diagnosis of unresectable sigmoid colon cancer accompanied by severe peritoneal dissemination and therefore performed only transverse colostomy in April, 2006.
  • FOLFOX4 therapy was started on April, 2006.
  • We started S-1 as second-line chemotherapy in May, 2007.
  • There was primary lesion re-growth after 4 cycles, so we changed to S-1+CPT-11 therapy.
  • Chemotherapy is now continued on an outpatient basis, 24 months after the medical treatment started.
  • FOLFOX4 therapy is useful for patients with advanced colon cancer accompanied by peritoneal dissemination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / therapeutic use. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098417.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


11. Angelopoulos S, Kanellos I, Christophoridis E, Tsachalis T, Kanellou A, Betsis D: Five-year survival after curative resection for adenocarcinoma of the colon. Tech Coloproctol; 2004 Nov;8 Suppl 1:s152-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year survival after curative resection for adenocarcinoma of the colon.
  • BACKGROUND: The purpose of this study was to evaluate the 5-year survival of patients with colon adenocarcinoma that underwent elective or emergency curative surgical treatment.
  • Among the patients, 26 underwent right colectomy, 3 transverse colectomy, 13 left colectomy and 38 sigmoidectomy.
  • All patients classified as TNM stage III underwent adjuvant chemotherapy.
  • Patient's sex and age, mucinous characteristics of the tumour and tumour location did not significantly affect survival.
  • Although patients with good tumour differentiation had the highest 5-year survival, this difference was not statistically significant (p=0.211).
  • CONCLUSIONS: The treatment of colon adenocarcinoma with curative resection by the end of the 20th century is accompanied with acceptable rates of overall 5-year survival.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Age Distribution. Aged. Aged, 80 and over. Colonoscopy. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655605.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Mizushima T, Sando K, Ito T, Mikata S, Nonaka K, Ide H, Michiura T, Kainuma S, Yamanaka H, Iwase K: [A case of advanced colon cancer responding completely to systemic 5-fluorouracil/l-leucovorin therapy]. Gan To Kagaku Ryoho; 2004 Nov;31(12):2047-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced colon cancer responding completely to systemic 5-fluorouracil/l-leucovorin therapy].
  • A 79-year-old man was admitted for advanced transverse colon cancer with large bowel obstruction.
  • The primary lesion was unresected and transverse colostomy was made.
  • Systemic chemotherapy with 5-fluorouracil and l-leucovorin was scheduled for a total of 4 courses postoperatively.
  • There was no severe side effect during chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Colostomy. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Neoplasm Invasiveness

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15570938.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Rajkumar D, Prakash A, Arya SV, Sinha AN: Adenosquamous carcinoma of colon. Indian J Gastroenterol; 2001 Nov-Dec;20(6):241-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of colon.
  • Primary adenosquamous carcinoma of the colon is an aggressive entity.
  • We report a 41-year-old man with a combination of adenocarcinoma and squamous cell carcinoma of the cecum, treated by right hemicolectomy and ileo-transverse anastomosis.
  • Postoperatively he received adjuvant chemotherapy.
  • However, the tumor recurred at the original site within two months and thereafter the patient was lost to follow up.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Cecal Neoplasms / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11817779.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


14. Procacciante F, Caciolo F, Diamantini G, Flati D, Pitasi F, Abilaliaj V, Covotta A, Banelli E, Di Seri M, Citone G: [Integrated multidisciplinary treatment of colorectal neoplasms]. Chir Ital; 2009 Jan-Feb;61(1):1-10
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Integrated multidisciplinary treatment of colorectal neoplasms].
  • In this retrospective study, the modality and advantages of the multidisciplinary diagnostic work-up and therapy regarding colorectal neoplasm were analysed.
  • Over the period 2004-2008, 63 patients underwent multidisciplinary treatment for colorectal cancer.
  • Exeresis was supplemented by adjuvant chemotherapy in those cases beyond IIA stage; all cases of extraperitoneal rectal and anal canal neoplasms plus one case of carcinoma of the transverse colon, initially inoperable, underwent neoadjuvant radiotherapy plus chemotherapy.
  • The treatment was initiated approximately 3 weeks after the diagnosis.
  • Fifty-four percent of patients with colonic and upper rectal neoplasms were given adjuvant chemotherapy, starting around 4 weeks after surgery.
  • Exeresis was performed in those patients with extraperitoneal rectal and anal canal neoplasms (12.7%) about 6-8 weeks after they had completed neoadjuvant therapy.
  • At the end of the treatment, 76% of the overall total numbers of patients were in good condition (follow-up 4-50 months).
  • The remaining 24% suffered recurrences about 13 months after the treatment for colonic and upper rectal neoplasm, and 8 1/2 months after treatment for extraperitoneal rectal/anal canal neoplasms.
  • Seventy-five percent of the recurring cases underwent treatment again, with 50% success; the others are still undergoing treatment.
  • The best therapeutic results were obtained by programmed integration of the various diagnostic-therapeutic steps according to an algorithm which we elaborated to evaluate all types of neoplasm at any stage of illness.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / radiotherapy. Colorectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colectomy. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Laparoscopy. Laparotomy. Leucovorin / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Organoplatinum Compounds / therapeutic use. Positron-Emission Tomography. Postoperative Complications. Radiography, Abdominal. Radiotherapy Dosage. Radiotherapy, Adjuvant. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19391334.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


15. Oñate-Ocaña LF, Herrera-Goepfert R, Aiello-Crocifoglio V, Mondragón-Sánchez R, Ruiz-Molina JM: [Multiorgan resection in T4 colonic adenocarcinoma. Report of a case]. Rev Gastroenterol Mex; 2000 Jan-Mar;65(1):26-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Resección multiorgánica en adenocarcinoma de colon T4. Informe de un caso.
  • To resect or not such a tumor is a difficult decision.
  • OBJECTIVE: To report a case of colon cancer with multivisceral invasion resected and to review the published information.
  • CLINICAL MATERIAL: A 43 year-old Mexican male with rectal bleeding and weight loss with a tumor located in transverse colon with direct invasion to stomach.
  • En-bloc radical-extended right colectomy, total gastrectomy, distal pancreatectomy, splenectomy and left adrenalectomy was performed.
  • Adjuvant chemotherapy was used.
  • [MeSH-minor] Adrenalectomy. Adult. Antimetabolites, Antineoplastic / therapeutic use. Colectomy. Fluorouracil / therapeutic use. Gastrectomy. Humans. Leucovorin / administration & dosage. Leucovorin / therapeutic use. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Pancreas / surgery. Pancreatectomy. Remission Induction. Spleen / pathology. Spleen / surgery. Splenectomy. Stomach / pathology. Stomach / surgery

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11464588.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 8
  •  go-up   go-down


16. Bilchik AJ, DiNome M, Saha S, Turner RR, Wiese D, McCarter M, Hoon DS, Morton DL: Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg; 2006 Jun;141(6):527-33; discussion 533-4
Hazardous Substances Data Bank. Isosulfan blue .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective multicenter trial of staging adequacy in colon cancer: preliminary results.
  • MAIN OUTCOME MEASURES: Micrometastases greater than 0.2 mm but less than 2 mm and isolated tumor cells less than 0.2 mm were defined according to the sixth edition of the American Joint Committee on Cancer Cancer Staging Manual.
  • Sixty-eight patients (52%) underwent a right hemicolectomy; 3 (2.3%), a transverse colectomy; 9 (7%), a left colectomy; 15 (11%), a sigmoid colectomy; 34 (26%), a low anterior resection; 1 (1%), an abdominal perineal resection; and 2 (2%), a total colectomy.
  • Of the 6 false-negative results, 4 were attributed to lymphatic channels obliterated by tumor.
  • CONCLUSIONS: In a multicenter trial, ultrastaging of colon cancer is feasible and accurate.
  • Surgical technique (adequate lymph node retrieval) and focused pathological analysis may improve staging accuracy and the selection of patients for chemotherapy.
  • The unnecessary toxicity and expense of chemotherapy may be avoided in those patients who are truly node negative.
  • [MeSH-minor] Aged. Colectomy. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Neoplasm Staging. Prognosis. Prospective Studies. Rosaniline Dyes

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785352.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA090848
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Rosaniline Dyes; 39N9K8S2A4 / iso-sulfan blue
  •  go-up   go-down


17. Tamura S, Miki H, Okada K, Miyake T, Yoshimura M, Suzuki R, Nakahira S, Nakata K, Okamura S, Sugimoto K, Takatsuka Y: Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer. Int J Clin Oncol; 2008 Dec;13(6):536-40
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is no standard treatment for peritoneal dissemination from gastric cancer.
  • A novel combination chemotherapy has been introduced for patients with advanced gastric cancer with peritoneal metastasis.
  • They were diagnosed with unresectable gastric cancer with severe peritoneal dissemination by staging laparoscopy, or with metastasis to the transverse colon.
  • We selected combined chemotherapy with both paclitaxel and S-1.
  • After five courses of this therapy, the primary gastric tumors were evaluated by conventional examinations, and second-look laparoscopy was performed to assess the efficacy of the treatment against the peritoneal metastases.
  • RESULTS: After five courses, primary tumor reductions were confirmed, and no cancer cells were detected on pathocytological investigation during second-look laparoscopy in any of the patients.
  • Three patients died, at 8, 15, and 29 months, respectively, after the initial treatment, and one has been alive for 54 months without recurrence.
  • CONCLUSION: This chemotherapy can be used in the treatment of patients with peritoneal metastasis of gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Drug Combinations. Female. Humans. Injections, Intraperitoneal. Male. Middle Aged. Neoplasm Staging. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Pilot Projects. Survival Rate. Tegafur / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1993 Mar-Apr;17(2):256-61; discussion 261-2 [8511923.001]
  • [Cites] Br J Cancer. 2006 Dec 18;95(12):1642-7 [17133268.001]
  • [Cites] Oncology. 2003;64(2):176-82 [12566916.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):25-30 [11957041.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):661-5 [16621433.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2620-4 [9704711.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2307-11 [9635521.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3380-4 [2720692.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Nov;29(12):2164-7 [12484028.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Cancer Lett. 2004 Jul 16;210(2):189-96 [15183534.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3402-7 [16740764.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):811-5 [12066214.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Br J Cancer. 1994 Feb;69(2):235-41 [8297720.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):629-31 [1347336.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1485-91 [1355523.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):370-5 [15739249.001]
  • [Cites] Oncology. 1993 Sep-Oct;50(5):338-43 [8378028.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):14-19 [11957065.001]
  • [Cites] Oncology. 2000 Feb;58(2):96-107 [10705236.001]
  • [Cites] Gastric Cancer. 2007;10(4):251-5 [18095081.001]
  • (PMID = 19093182.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. West NP, Morris EJ, Rotimi O, Cairns A, Finan PJ, Quirke P: Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol; 2008 Sep;9(9):857-65
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study.
  • We aimed to assess the quality of colon cancer surgery by studying the extent of variation in the plane of surgical resection, the amount of tissue removed, and its association with survival.
  • METHODS: All resections for primary colon adenocarcinoma done at Leeds General Infirmary (Leeds, UK) between Jan 1, 1997, and June 30, 2002, were identified.
  • Tissue morphometry was done on 253 tumours.
  • Mean cross-sectional tissue area outside the muscularis propria was significantly higher with mesocolic plane surgery (mean 2181 [SD 895] mm(2)) compared with intramesocolic (mean 2109 [1273] mm(2)) and muscularis propria plane (mean 1447 [913] mm(2)) surgery (p=0.0003).
  • There was also a significant increase in the distance from the muscularis propria to the mesocolic resection margin with mesocolic plane surgery (mean 44 [21] mm) compared with intramesocolic (mean 30 [16] mm) and muscularis propria plane (mean 21 [12] mm) surgery, which was independent of tumour site (all excisions p<0.0001).
  • The plane of surgery and amount of mesocolon removed varied between the different sites with better planes in left-sided resections than right-sided ones, which were better than transverse resection (p<0.0001).
  • INTERPRETATION: As previously shown in the rectum, we have now shown there is marked variability in the plane of surgery achieved in colon cancer.
  • If confirmed by clinical trial data, such as from the ongoing National Cancer Research Institute Fluoropyrimidine, Oxaliplatin and Targeted Receptor pre-Operative Therapy for colon cancer (FOxTROT) trial of neoadjuvant chemotherapy in advanced resectable colon cancer, improvement of the plane of dissection might be a new cost-effective method of decreasing morbidity and mortality in patients with colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / standards. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / prevention & control. Quality of Health Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2008 Sep;9(9):815-7 [18760238.001]
  • (PMID = 18667357.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 9805; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


19. Bonatti H, Bodner G, Obrist P, Bechter O, Wetscher G, Oefner D: Skin implant metastasis after percutaneous radio-frequency therapy of liver metastasis of a colorectal carcinoma. Am Surg; 2003 Sep;69(9):763-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin implant metastasis after percutaneous radio-frequency therapy of liver metastasis of a colorectal carcinoma.
  • A 56-year-old man underwent resection of the transverse colon for an adenocarcinoma (pT3N2M0) following by adjuvant chemotherapy.
  • He developed multiple liver metastases and underwent RFA.
  • Ultrasound examination and computed tomography scan revealed an intracutaneous tumor of 2-cm diameter.
  • The tumor was excised and revealed a metastasis of the previously described adenocarcinoma.
  • CPT-11 monotherapy was started; however, due to tumor progression, the patient died 35 months after colonic resection and 10 months after RFA.
  • [MeSH-major] Adenocarcinoma / secondary. Catheter Ablation / adverse effects. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Neoplasm Seeding. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14509323.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Sakakibara T, Kurasawa T, Narumi K, Kamano T, Tsurumaru M: T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case. Surg Today; 2002;32(6):536-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upper and lower gastrointestinal examinations did not reveal any abnormal findings, but an abdominal aortic aneurysm was diagnosed by computed tomography, and thus was determined to be the source of the pain.
  • The patient was referred to our hospital to undergo a grafting operation; however, a laparotomy performed in July 1997 revealed an unexpected small intestinal tumor, and therefore a partial ileectomy between 15 and 70cm in an oral direction from the terminal ileum was carried out instead.
  • Metastasis of the facial skin and local recurrence were recognized 5 months later, and chemotherapy with THP-COP and ESHAP only resulted in progressive disease.
  • An autopsy revealed three fistulas caused by metastatic tumors, one of which communicated with the duodenum from the ileum, one with the skin from the ileum, and one to the transverse colon from the ileum.
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12107782.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


21. Gervaz P, Bucher P, Morel P: Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol; 2004 Dec 15;88(4):261-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Embryological and physiological data suggest that proximal (in relation to the splenic flexure) and distal parts of the colon represent distinct anatomical and functional entities.
  • Since 1990, molecular biologists have identified two distinct pathways, microsatellite instability (MSI) and chromosomal instability (CIN), which are involved in the pathogenesis of colon cancer (CC).
  • (1) tumors originating from the proximal colon have a better prognosis due to a high percentage of MSI-positive lesions; and (2) location of the neoplasm in reference to the splenic flexure should be documented before group stratification in ongoing trials of adjuvant chemotherapy for CC.
  • In the future, clinical decision-making regarding adjuvant chemotherapy might be stratified according to the MSI status of cancers located proximally to the splenic flexure.
  • [MeSH-major] Chromosomal Instability. Colon / anatomy & histology. Colonic Neoplasms / genetics. Loss of Heterozygosity. Microsatellite Repeats
  • [MeSH-minor] Chemotherapy, Adjuvant. Colon, Transverse / anatomy & histology. Colon, Transverse / pathology. Genes, DCC. Genes, p53. Humans. Mutation. Neoplasm Staging. Phenotype. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15565587.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 53
  •  go-up   go-down


22. Galbfach PJ, Sygut AR, Spychalski MI, Winiarski MJ, Dziki AJ: [Squamous cell carcinoma of caecum--case report]. Pol Merkur Lekarski; 2009 Jun;26(156):640-1
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell cancer is a very rare malignancy in colon and rectum.
  • It accounts for 0.05-0.1% of all types of cancers in this localization.
  • In the article we present a case of 77 year old women who was operated due to tumor of caecum which infiltrated the proximal transverse colon.
  • Histopathological examination of removed tumor revealed squamous cell carcinoma of caecum in pT4 stage.
  • In the Clinic retrospective material squamous cell cancer of colon accounts for 0.07% of the total colon cancer cases.
  • The patient was disqualified from post-operative chemotherapy because of the age and general condition.
  • Despite the radical surgical treatment the course of the disease was rapid.
  • [MeSH-minor] Aged. Colectomy. Fatal Outcome. Female. Humans. Liver Neoplasms / secondary. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711732.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


23. Michalopoulos A, Papadopoulos V, Zatagias A, Fahantidis E, Apostolidis S, Haralabopoulos E, Netta S, Sasopoulou I, Harlaftis N: Metastatic breast adenocarcinoma masquerading as colonic primary. Report of two cases. Tech Coloproctol; 2004 Nov;8 Suppl 1:s135-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The colon is the rarest site of metastasis for the breast carcinoma.
  • PATIENTS AND RESULTS: We report our recent experience of two female patients, 55 and 57 years old respectively, who presented breast metastasis at the proximal transverse colon.
  • They were operated for breast carcinoma followed by chemotherapy and radiotherapy, four and ten years before the metastasis was diagnosed.
  • Diagnosis was made by double contrast barium enema and colonoscopy.
  • Postoperatively, both patients received systemic chemotherapy.
  • CONCLUSIONS: Patients with history of breast cancer presenting with anaemia and/or bowel obstruction should be examined for possible metastasis to colon and should be treated surgically followed by systemic chemotherapy.
  • [MeSH-minor] Anastomosis, Surgical. Biopsy, Needle. Chemotherapy, Adjuvant. Colectomy / methods. Colonoscopy. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Mastectomy / methods. Middle Aged. Neoplasm Staging. Risk Assessment. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655598.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol; 2003 Aug;90(2):390-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.
  • METHODS: Patients (408) with stage IIIC epithelial ovarian cancer had cytoreductive surgery before systemic platinum-based combination chemotherapy.
  • (1) right upper quadrant (diaphragm/hepatic, and adjacent peritoneal surfaces), (2) left upper quadrant (omentum/gastro-colic ligament, spleen, stomach, transverse colon, splenic flexure of colon), (3) pelvis (reproductive organs, recto-sigmoid, pelvic peritoneum), (4) retroperitoneum (pelvic/aortic nodes), and (5) central abdomen (small bowel, ascending/descending colon, mesentery, anterior abdominal wall, pericolic gutters).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12893206.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Tangour-Bouaicha M, Bel Haj Salah M, Ben Brahim E, Ben Othmène M, Douggaz A, Sassi S, Chatti-Dey S: [Primary peritoneal yolk sac tumour. A case report]. Ann Pathol; 2010 Oct;30(5):378-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary peritoneal yolk sac tumour. A case report].
  • Abdominal exploration disclosed a large mass involving mesentery of the transverse colon associated to three hepatic nodules and abundant peritoneal bleeding.
  • Microscopic examination of the pathologic specimen concluded to a yolk sac tumour.
  • Patient underwent intensive chemotherapy; she's free of disease 2 years after diagnosis.
  • Through this case, clinicopathologic features of this rare neoplasm will be discussed.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 21055525.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


26. Kameyama H, Takii Y, Nomura T, Nakagawa S, Yabusaki H, Tsuchiya Y, Nashimoto A, Tanaka O: [Three cases of complete response after treatment with UFT and leucovorin for recurrent colorectal cancer]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1951-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of complete response after treatment with UFT and leucovorin for recurrent colorectal cancer].
  • We report three cases of complete response (CR) after treatment with UFT/LV for recurrent colorectal cancer.
  • Metastatic lesions of the liver completely disappeared on computed tomography(CT)one month after chemotherapy.
  • Case 2: A 66-year-old man who underwent left colectomy and partial hepatectomy for transverse colon cancer and descending colon cancer with liver metastasis was determined to have multiple lung metastases.
  • UFT/LV therapy was started.
  • CT revealed the disappearance of the tumor after 7 courses of UFT/LV therapy.
  • Recurrence was not observed for 22 months, and the treatment has been discontinued.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Leucovorin / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoembryonic Antigen / blood. Female. Humans. Male. Tegafur / therapeutic use. Tomography, X-Ray Computed. Uracil / therapeutic use

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011350.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin; 1-UFT protocol
  •  go-up   go-down


27. Catani M, De Milito R, Simi M: [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. Chir Ital; 2005 Jan-Feb;57(1):127-33
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
  • [Transliterated title] Nuovi orientamenti nella cura dei tumori stromali gastroenterici (GIST) avanzati e metastatici: trattamento combinato intervento chirurgico-terapia sistemica con imatinib in un caso a localizzazione primitiva gastrica.
  • Gastrointestinal stromal tumours (GIST) are rare neoplasms originating from connective tissue in the digestive tract with an incidence of less than 1% and account for most non-epithelial primitive digestive tumours.
  • Metastasis diagnosed at the time of disease discovery confirms GIST malignancy.
  • Resistance to conventional chemotherapy is commonly shown by malignant GIST.
  • At the time of the first operation the patient had lost 10 kg body weight over the previous months and was seriously cachectic.
  • Considering the action mechanism of imatinib and the extent of the lesion we decided to perform a total gastrectomy procedure.
  • At the time of the operation the stomach seemed to have a modified volume and shape: it appeared to be divided into two sacs, the larger and deeper of which was the original gastric cavity, while the superficial, smaller one seemed to be a protrusion of the organ.
  • The stomach was indistinguishable from the spleen, the transverse colon and the distal pancreatic tract.
  • The neoplasm was directly linked to the left liver and to the inferior diaphragmatic surface.
  • We performed total gastrectomy and resection of the tail of the pancreas, the spleen, and the transverse colon all in one and the same session.
  • The patient was discharged on postoperative day 8 and commenced imatinib therapy 30 days after the operation with 4 tablets per day.
  • One year after the operation the outcome appears to be lasting and the patient has tolerated the drug treatment well.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrectomy. Gastrointestinal Stromal Tumors / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Benzamides. Humans. Imatinib Mesylate. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832750.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


28. Wright CL, Stewart ID: Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am J Surg Pathol; 2003 Nov;27(11):1393-406
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with these tumors have an improved prognosis and may show greater sensitivity to chemotherapy.
  • MMR-d tumors presented at an earlier stage than intact tumors, and the node-positive MMR-d tumors were less likely than intact tumors to have pericolonic extranodal tumor deposits (18.2% vs. 44%).
  • The proportion of tumors at each site that were MMR-d increased progressively from cecum (32%) to ascending (35%) to transverse colon, where 41% of all tumors were defective.
  • Both types of MMR-d tumors more often had expansive borders, intraepithelial lymphocytosis, peritumoral lymphoid, and Crohn's-like lymphoid responses than the intact tumors; the frequencies of these features diminished with advancing stage.
  • Tumor budding was less common in stage II and III MMR-d tumors than in intact tumors.
  • Keloid and myxoid type stromas correlated with stage and vascular invasion and were not related to mismatch repair status.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Carrier Proteins. Colon, Ascending / chemistry. Colon, Ascending / pathology. Colon, Descending / chemistry. Colon, Descending / pathology. DNA, Neoplasm / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. MutS Homolog 2 Protein. Neoplasm Proteins / analysis. Neoplasm Proteins / genetics. Neoplasm Staging. Neoplasms, Second Primary. Nuclear Proteins. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14576472.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


29. Caudry M, Ratoanina JL, Escarmant P, Maire JP: [Target volume in radiotherapy of gastric adenocarcinoma]. Cancer Radiother; 2001 Oct;5(5):523-33
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les volumes-cibles de la radiothérapie des adénocarcinomes gastriques.
  • A GTV should be considered in preoperative or exclusive radiation therapy.
  • a) A "tumor bed" volume.
  • Parietal infiltration may extend beyond macroscopic limits of the tumor, especially in "linitis plastica".
  • Therefore this volume will include: the tumor and the remaining stomach or their "bed of resection", a part of the transverse colon, the duodenum, the pancreas and the truncus of the portal vein.
  • (1) contiguous microscopic extension from deeply invasive T3 and T4 tumors, that remain amenable to local sterilization with doses of 45-50 Gy, delivered in a CTV including the peritoneal cavity at the level of the gastric bed, and under the parietal incision;.
  • (2) true "peritoneal carcinomatosis", with widespread seeds, where chemotherapy (systemic or intraperitoneal) is more appropriate.
  • In distal and proximal tumors, involvement of resection margins is of poor prognosis--a radiation boost must be delivered at this level.
  • In tumors invading the distal esophagus, a more complete coverage of mediastinal lymph nodes should be considered, especially in patients in good general condition.
  • In contrast, for distal tumors, the hepatic pedicle and the hepatoduodenal ligament should be included whereas the splenic area could be spared.
  • CONCLUSION: Planning the treatment of gastric cancer remains difficult; target volumes must be customized by experienced radiation oncologists according to tumoral and clinical situation.
  • [MeSH-minor] Dose Fractionation. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm, Residual

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11715304.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


31. Ohuchi S, Kotanagi H, Kamata S, Sakusabe M, Seki H, Sawata T, Kumagai Y: [A case of peritoneal dissemination of postoperative primary duodenal cancer successfully treated by TS-1 therapy]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1179-81
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of peritoneal dissemination of postoperative primary duodenal cancer successfully treated by TS-1 therapy].
  • An endoscopic examination detected a type 2 tumor of the descending limb of the duodenum.
  • With a diagnosis of adenocarcinoma based on the biopsy finding, the patient was subjected to surgery.
  • Laparotomy revealed the presence of a duodenal tumor disseminating to the omentum at the site where the transverse colon is attached.
  • Pancreatoduodenectomy and partial resection of the transverse colon were carried out.
  • CT conducted 6 months after surgery did not show any signs of tumor recurrence; but one year later, extensive tumor dissemination was noted on the hepatic surface.
  • Upon consultation with the patient, a regimen of 80 mg/day of TS-1 given for 4 weeks followed by 2 weeks of a drug-free period was initiated.
  • Six months later, the growth of tumor became arrested, improving his QOL.
  • Nine months later, the tumor growth was progressive and the patient died two years after operation.
  • The TS-1 regimen applied in the present case may constitute a therapeutic strategy to be considered for similar conditions in future.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Duodenal Neoplasms / drug therapy. Neoplasm Seeding. Omentum / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Colectomy. Drug Combinations. Humans. Liver / pathology. Male. Middle Aged. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121925.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


32. Miquel C, Sabourin JC, Elias D, Grandjouan S, Viguier J, Ducreux M, Duvillard P, Praz F: An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer. Hum Pathol; 2004 Dec;35(12):1564-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer.
  • Gastrointestinal carcinoid tumors are often associated with other tumors, particularly colon adenocarcinomas; but the association between carcinoid tumors and hereditary nonpolyposis colorectal cancer (HNPCC) syndrome has not yet been explored.
  • We report an unusual case of a 28-year-old woman with HNPCC who underwent surgery for a transverse colon adenocarcinoma in whom an appendix carcinoid tumor was incidentally found.
  • To assess whether the carcinoid tumor displayed the characteristic molecular features of HNPCC tumors, we investigated the expression of mismatch-repair (MMR) proteins and microsatellite instability (MSI) status in both tumors.
  • Interestingly, the adenocarcinoma exhibited an MSI phenotype but the carcinoid tumor did not, indicating that these 2 tumors arose through different molecular pathways.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Carcinoid Tumor / pathology. Colonic Neoplasms / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. DNA, Neoplasm / analysis. DNA-Binding Proteins / analysis. Drug Therapy, Combination. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Microsatellite Repeats / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15619218.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MSH3 protein, human; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement